Sep 09,2019

Insilico Medicine Raises $37M in Series B Funding

Insilico Medicine, a Hong Kong-based developer of next-generation artificial intelligence technology for drug discovery, completed a $37m Series B funding round. The round was led by Qiming Venture Partners, joined by Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu Ventures, Pavilion Capital, Bold Capital Partners and others. The company intends to use the funds to: � commercialize the validated generative chemistry and target identification technology, � build up a senior management team with the experience in the pharmaceutical industry, � further develop its pipeline in cancer, fibrosis, NASH, immunology and CNS for the purposes of partnering with the pharmaceutical companies on specific therapeutic programs.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

Bayer leads $25m investment round for healthcare start-up Medopad

Digital healthcare start-up Medopad has earned $25m in an investment round led by Leaps by Bayer, the German pharmaceutical multinational�s venture capital arm. The investment, which brings Medopad�s total funding to over $50m, will be used to help develop the company�s digital health platform and to fund new clinical studies.The investment will support clinical trials on these conditions, as well as heart condition Aortic Stenosis.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jan 13,2020

Concerto HealthAI Raises $150 Million in Series B Funding

Concerto HealthAI, the market leader for Real-World Data (RWD) and enterprise AI technology solutions for Precision Oncology, announced today it has raised $150 million in aggregate Series B financing. The round of financing was led by Declaration Partners with participation from Maverick Ventures, AllianceBernstein PCI, and SymphonyAI Group. As part of the transaction, Andrew Goldfarb, partner at Declaration Partners, and Leif Pedersen, senior operating partner at SymphonyAI Group, will join Concerto HealthAI�s board. Romesh Wadhwani, founder and CEO of SymphonyAI Group, will continue as executive chairman, and Jeff Elton, PhD, CEO of Concerto HealthAI as board member. The Series B funding will support Concerto HealthAI�s continued innovation in RWD and technology products and services for regulatory and non-regulatory applications, expansion into adjacent therapy areas, and commercial patient solutions.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 03,2022

CancerIQ Raises $14M Series B Funding to Improve Access to Innovations in Cancer Early Detection and Prevention

CancerIQ, the platform powering early cancer detection and prevention across broad patient populations, announced today it closed a $14 million Series B financing round co-led by Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures. McKesson Ventures, OSF Ventures (the investment arm of OSF HealthCare, a current CancerIQ customer), as well as CancerIQ�s Series A lead investor, HealthX Ventures, also participated in the Series B round. The new funding will help CancerIQ grow its precision health platform, strengthen its partnership ecosystem, and expand its health system network. Following a recent series of key executive hires, the company also plans to hire 50 team members to meet the rising demand for more efficient and innovative cancer prevention services.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jun 08,2022

French AI biotech startup Owkin gets $80-million shot from Bristol Myers Squibb

Parisian AI biotech unicorn Owkin has brought in $80 million as it partners with the US-based pharmaceutical giant Bristol Myers Squibb on drugs trials. The new partnership could be transformational for patient outcomes and scientific progress, making machine learning solutions an integral part of the clinical trial process. The $80 million will be split between a Series B-1 equity round, led by Bristol Myers Squibb, and up-front fees for clinical trials for cardiovascular drugs using Owkin's technology. The fresh funding brings the company's total raised to over $300 million. Owkin will use the investment to support its data generation strategy in multiple therapeutic areas with a strong focus on multimodal and rich biological data, including the most advanced spatial single-cell omics technologies.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jun 15,2022

DermaSensor raises $10M as it braces for U.S. launch

DermaSensor announced today that it raised an additional $10 million as it prepares for a commercial launch in the U.S. DermaSensor said the oversubscribed $10 million financing was led by existing investors, including Ceros Capital Markets. With the newly secured funding, the company is hiring for a range of roles, including chief commercial officer.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 07,2015

Livongo Health Raises $20 Million in Series B Funding From Kleiner Perkins Caufield & Byers, DFJ and General Catalyst

Livongo Health, a consumer digital health company that is empowering people with chronic diseases to live better, announced today that it has secured $20 million in Series B funding from investors including Kleiner Perkins Caufield & Byers (KPCB), DFJ and previous investor General Catalyst. The funding will enable the company to further develop its chronic disease management ecosystem and accelerate the adoption of the company's digital diabetes management program, Livongo for Diabetes(TM), among self-insured employers, healthcare providers and payers. Dr. Beth Seidenberg, General Partner at KPCB, and Emily Melton, Partner at DFJ, will be joining Livongo Health's Board of Directors.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Dec 17,2015

WellDoc closes $22 million Series B

A Baltimore-based health IT startup that initially rolled out its product for diabetes care in Maryland closed on $22 million in financing, and is looking to scale nationally. WellDoc’s Series B was led by Samsung Ventures, and existing investor Merck Global Health Innovation Fund was a co-lead. Also participating in the round was Adage Capital Management, Excel Venture Management, Alexandria Venture Investments and Hudson River Capital Partners. The company, which has offices near Penn Station, plans to use the money for further development of its product, BlueStar. The mobile app helps doctors and patients manage Type 2 diabetes.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jan 22,2016

New video game aims to help kids with ADHD

Akili Interactive Labs, Inc. just raised $30.5 million in venture capital funding to support clinical development for a game called "Project: EVO." The developers hope it could be a game changer in helping people with ADHD. Akili aims to apply for FDA clearance and launch the product in 2017, according to a press release announcing the funding.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jul 20,2016

Akili Adds Amgen Ventures and M Ventures* to Series B Financing, Increasing Round to $42.4 Million

Akili Interactive Labs, Inc. ("Akili"), a digital medicine company developing novel, non-pharmacological therapeutics and diagnostics for cognitive disorders, today announced an $11.9 million expansion of its recent Series B financing. *Merck Ventures BV, Amsterdam, The Netherlands, a subsidiary of Merck KGaA, Darmstadt, Germany (known as M Ventures in the United States and Canada), and Amgen Ventures, the venture arm of Amgen, joined existing investors to bring the total Series B proceeds to $42.4 million. Akili will use the funds to support and expand clinical development of its clinical-stage products into new areas, with an expanded focus on neurodegeneration, and to build out its commercial infrastructure as Akili nears the market with its late-stage products.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to SERIES B